Miguel Emilio Morilla, MD; Jeffrey Kocher, MD; Marco Harmaty, MD
Potential Conflicts of Interest: None disclosed.
Morilla M., Kocher J., Harmaty M.; Localized Amyloidosis at the Site of Enfuvirtide Injection. Ann Intern Med. 2009;151:515-516. doi: 10.7326/0003-4819-151-7-200910060-00017
Download citation file:
Published: Ann Intern Med. 2009;151(7):515-516.
Background: Enfuvirtide is the first of a new class of antiretroviral agents that block fusion of the viral particle with the host target cell. Its safety and antiviral activity have been demonstrated (1, 2). In clinical trials, injection site reactions occurred in 80% to 100% of patients (3). The most common signs and symptoms reported were induration in 94%, erythema in 91%, and subcutaneous nodules and cysts in 70% (4).
Objective: To describe a case of amyloidosis at the injection site of enfuvirtide.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only